Tag: Ovarian Cancer

May 30, 2019

OncBioMune Announces Initial In Vitro Proof-of-Concept Data for PGT in a Multi-Drug Resistant Ovarian Cancer Model

OncBioMune Pharmaceuticals (OTCQB:OBMP) has announced results of its in vitro data for PGT in a multi-drug resistant ovarian cancer model....
September 28, 2018
May 9, 2018

OncoMed Announces First Quarter 2018 Financial Results and Operational Highlights

OncoMed Pharmaceuticals (NASDAQ:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced first quarter 2018...
April 30, 2018

8 Glioblastoma Treatment Stocks

With an average survival rate of 16 months, glioblastoma is the most common and deadly type of brain cancer, accounting...
April 30, 2018

Cytori Provides Update on US Manufacturing and EU Approval Plans for ATI-0918, Liposomal Doxorubicin

Cytori Therapeutics (Nasdaq:CYTX) provided an update on its plans for US manufacturing and EU approval for its ATI-0918 liposomal doxorubicin product....
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 24, 2018

Immunovaccine and Incyte Expand Collaboration

Collaborations are allow companies sharing scientific integrity to build their pipelines without giving away the rights to their products.